KUS121 low dose

Phase 2Small molecule

KKyoto Drug Discovery and Development Co., Ltd.

KUS121 low dose is one of 5 small molecule programs targeting Retinal Artery Occlusion. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinal Artery OcclusionActive, not recruiting

Retinal Artery OcclusionPhase 2

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Retinal Artery Occlusion

#DrugCompanyPhaseTrials

Bayer Aspirin

Tnkase

1 3

Activase

Roche

Phase 3

1 4

Acetylsalicylic Acid

Bayer

Phase 3

1 5

KUS121 low dose

KKyoto Drug Discovery and Development Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Retinal Artery Occlusion1 trial

A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)

Completed·KKyoto Drug Discovery and Development Co., Ltd.·Phase 2·NCT06178055·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KUS121 low dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KUS121 low dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KUS121 low dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kyoto Drug Discovery and Development Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKyoto Drug Discovery and Development Co., Ltd.

KUS121 low dose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Retinal Artery Occlusion1 trial

References

Drug Info

Quick Facts

Related News